Courtagen Life Sciences Appoints Dr. Joe Keegan to the Company’s Board of Directors

▤ Summary

WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, Inc., a commercial-stage, innovative molecular information company that sells proprietary genomic diagnostic and drug metabolism assays for pediatric neurology disorders, announced today the appointment of Dr. Joe Keegan to the company’s Board of Directors. Keegan’s previous success in building private and public companies in the life sciences industry will add a valuable perspective to our Board of Directors,” states Brian McKernan, Chief Executive Officer of Courtagen. “We look forward to benefiting from Joe’s insights, and having him on the Courtagen Team.” Dr. Keegan has more than 30 years of experience in life science businesses. During his 9 year tenure as CEO at Molecular Devices Corporation, Dr. Keegan grew the companys revenues from $30M to $185M through internal growth and acquisitions. He currently serves on the Boards of Directors of Advanced Cell Diagnostics, Courtagen Life Sciences, Labcyte Corporation as Chairman, Optofluidics, Inc., Response Biomedical Corporation (RBM:Toronto), Seahorse Bioscience Inc., Stereotaxis, Inc. (Nasdaq: STXS), Unchained Labs, Inc., Wasatch Microfluidics, Inc., ALDA as Past Chairman and the San Francisco Opera.

▦ Linked Companies

ForteBio

$1B+